Tina Liedtky has over 20 years of leadership experience in the medical device and diagnostics industry. As President, Transplant Diagnostics, Tina is responsible for the strategic direction and growth of Thermo Fisher Scientific’s transplant diagnostics portfolio across the patient care continuum. Previously, she served as President, Clinical Diagnostics, managing a broad portfolio of businesses within Thermo Fisher’s Specialty Diagnostics Group. Prior to joining Thermo Fisher, Tina led US and global commercial teams for the Diabetes Care and Rapid Diagnostics divisions of Abbott Laboratories, as well as sales and marketing leadership roles at Medtronic, Covidien, and Boston Scientific.
Tina serves on the Board of Directors for Neurovalens, a non-invasive neuromodulation company based in Belfast, Ireland, and is actively involved with Miracle Babies, a nonprofit organization focused on supporting families with babies in the NICU. She holds a bachelor’s degree in cognitive neuroscience from Princeton University and an MBA from Harvard Business School.
Innovative transplant diagnostics and novel paradigms that give a clearer picture of a recipient’s immune system at various phases of the transplant journey can enable transplant teams to mitigate some of these challenges and make more accurate and faster donor assessments, as well as more informed and patient-centric decisions post-transplant.